metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population
versus paclitaxel
	pembrolizumab alone
	KEYNOTE-061 (all population), 2018 Lancet 2018; 392:123-133 NCT02370498	RCT	mGC or mGEJC - L2 - all population	pembrolizumab	paclitaxel	patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine	296 / 296	some concern	inconclusive	statistically significant 49 % increase in progression or deaths (PFS)
mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive
versus paclitaxel
	pembrolizumab alone
	KEYNOTE-061 (PDL1 CPS>1), 2018 Lancet 2018; 392:123-133 Gastric Cancer 2022; 25:197-206-. NCT02370498	RCT	mGC or mGEJC - L2 - PDL1 positive	pembrolizumab	paclitaxel	patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine (PDL1 CPS>1 population)	196 / 199	some concern	inconclusive	inconclusive 18 % decrease in deaths (OS) (PE) statistically significant 27 % increase in progression or deaths (PFS) (PE)